A randomised phase III trial of high dose palliative radiotherapy (HDPRT) versus concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/small volume metastatic NSCLC not suitable for radical chemo-radiotherapy.

The purpose of this study is to investigate whether adding chemotherapy to a short (less than six weeks) course of radiotherapy results in a greater improvement in symptoms and overall wellbeing (quality of life) compared with using a short course of radiotherapy alone in patients with Non-Small Cell Lung Cancer (NSCLC) who cannot be treated with surgery or a long (six weeks or longer) course of radiotherapy and chemotherapy.

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Final Accrual

76

Trial Chairperson

Associate Professor Margot Lehman, Princess Alexandra Hospital, QLD

Clinical Trial Registration

Related Post

26 November, 2025

TROG Member Prof Paul Keall’s innovative research recognised in two Premier’s Awards

LATEST NEWS; 26 November 2025 Medical physics researcher and

25 November, 2025

Automated quality assurance tool shows promise in TROG 18.01 NINJA trial

LATEST NEWS: 25 November 2025 Vital quality assurance (QA)